Company Overview of Actavis Holdings UK Limited
Actavis Holdings UK Limited operates as a pharmaceutical company that develops, manufactures, and distributes generic, branded, and biosimilar pharmaceutical products. It offers alenvona and cleosensa tablets, neotigason tablets, paracetamol solutions (for infusion), over-the-counter products, and fentanyl transdermal patch solutions. The company provides its products for the treatment of diseases in central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory, and anti-infective therapeutic categories. It serves patients and healthcare professionals worldwide. Actavis Holdings UK Limited was formerly known as Alpharma Ltd. and changed its name in May 2006. ...
Barnstaple, EX32 8NS
Founded in 1903
Key Executives for Actavis Holdings UK Limited
Executive Director of Finance & Information Technology
Managing Director of Operations
Executive Director of Human Resources
Vice President of UK & Ireland
Executive Director of Hospitals & Brands and Director
Compensation as of Fiscal Year 2014.
Actavis Holdings UK Limited Key Developments
Actavis UK Ltd. Wins Multiple Awardees Contract for Supplying Generic Transition Pharmaceuticals
Mar 16 15
Actavis UK Ltd. won a multiple awardees contract award from The Secretary of State of Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic transition pharmaceuticals. The lowest offer is GBP 6.5 million and the highest offer is GBP 7 million.
Actavis UK Wins Multiple Awardees Contract for Supplying Generic Transition Pharmaceuticals
Mar 13 15
Actavis UK Ltd. won a multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of generic transition pharmaceuticals (Contract Award Notice No.: 2015/S 050-086884). The lowest offer is £14.5 million and the high offer is £14.7 million.
Actavis Announces the Launch of Reltebon (Oxycodone) Prolonged Release Tablets
May 7 14
Actavis has announced the launch of a range of Reltebon (Oxycodone) Prolonged Release tablets which can provide up to a 30% value saving when compared to the originator brand. Available in 5mg x 28, 10mg x 56, 20mg x 56, 40mg x 56, 80mg x 56, Reltebon (Oxycodone) Prolonged Release is used to relieve severe pain, which can only be controlled by opioid analgesics. It is the bioequivalent of the branded originator product, has been manufactured with similar colour and shape tablets and is supplied in simple-to-use push-through blister packs. The launch of Reltebon (Oxycodone) Prolonged Release enhances the Actavis Pain Franchise following on from the launches of Lynlor (Oxycodone) Immediate Release Capsules and Hapoctasin Transdermal Patches (Buprenorphine). Reltebon (Oxycodone) Prolonged Release tablets are manufactured in the Actavis facility based in Barnstaple, UK. All products are available through major wholesalers or directly from the Actavis Telemarketing Team on freephone: 0800-731-0370 or by fax: 0800-731-0380.
Similar Private Companies By Industry
Recent Private Companies Transactions